Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone for diabetic nephropathy (phase 2, albuminuria and potassium)
2012-004179-38Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Finerenone various oral doses with Placebo (2 arms). Primary endpoint: Change in urinary albumin-to-creatinine ratio at day 90. Started Mar 2013; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004179-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004179-38.